A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer

Masuno, Tomiya; Kishimoto, Seiji; Ogura, Takeshi; Honma, Takeshi; Niitani, Hisanobu; Fukuoka, Masahiro; Ogawa, Norio

doi:10.1002/1097-0142(19911001)68:7<1495::aid-cncr2820680705>3.0.co;2-6

Cited by 59 publications

(35 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, some early reports have suggested that heat-killed Lactobacillus casei Shirota could be useful in the treatment of carcinoma of the uterine cervix (44, 45) and secondary to lung cancer (46). In one preclinical study, viable L. casei was found to be more effective than heat-killed L. casei in the prevention of secondary tumours in preimmunized mice (47).…”

Section: Clinical Benefits Of Probiotics – Is Viability Essential?mentioning

confidence: 99%

Probiotic viability – does it matter?

Lahtinen¹

2012

Microbial Ecology in Health & Disease

View full text Add to dashboard Cite

Section: Clinical Benefits Of Probiotics – Is Viability Essential?mentioning

confidence: 99%

Probiotic viability – does it matter?

Lahtinen¹

2012

Microbial Ecology in Health & Disease

View full text Add to dashboard Cite

“…5) [34][35][36][37][38] and intrapleural chemotherapy and immunotherapy ( Fig. 6) [39][40][41][42]. Talc was compared with other agents in nine studies that included 341 patients.…”

Section: Which Is the Best Agent For Pleurodesis?mentioning

confidence: 99%

The evidence on the effectiveness of management for malignant pleural effusion: a systematic review

Tan

Sedrakyan

Browne

et al. 2006

European Journal of Cardio-Thoracic Surgery

229

119

View full text Add to dashboard Cite

The aim of this study was to review systematically the available evidence on pleurodesis for malignant effusion, focusing on the choice of the agents, route of delivery and other strategies to improve outcomes. Four electronic databases (MEDLINE, EMBASE, Web of Science and Cochrane Controlled Trials Register) were searched, reference lists checked and letters requesting details of unpublished trials and data sent to authors of previous trials. Studies of malignant pleural effusion in humans were selected with no language restrictions applied. Criteria for randomised clinical trial (RCT) eligibility were random allocation of patients and non-concurrent use of another experimental medication or device. Methodological quality evaluation of the trials was based on randomisation, blinding, allocation concealment and intention to treat analysis. A random effect model was used to combine the relative risk estimates of the treatment effects whenever pooling for an overall effect was considered appropriate. Forty-six RCTs with a total of 2053 patients with malignant pleural effusions were reviewed for effectiveness of pleurodesis. Talc tended to be associated with fewer recurrences when compared to bleomycin (RR, 0.64; 95% CI, 0.34-1.20) and, with more uncertainty, to tetracycline (RR, 0.50; 95% CI, 0.06-4.42). Tetracycline (or doxycycline) was not superior to bleomycin (RR, 0.92; 95% CI, 0.61-1.38). When compared with bedside talc slurry, thoracoscopic talc insufflation was associated with a reduction in recurrence (RR, 0.21; 95% CI, 0.05-0.93). Strategies such as rolling the patient after instillation of the sclerosing agent, protracted drainage of the effusion and use of larger chest tubes were not found to have any substantial advantages. Talc appears to be effective and should be the agent of choice for pleurodesis. Thoracoscopic talc insufflation is associated with fewer recurrences of effusions compared with bedside talc slurry, but this is based on two small studies. Where thoracoscopy is unavailable bedside talc pleurodesis has a high success rate and is the next best option.

show abstract

“…When the malignancy is localized in the pleural cavity, intrapleural chemotherapy may treat the underlying neoplasm in addition to controlling the effusion [159,160]. To obtain maximal anticancer activity with minimal systemic side effects, however, a high intrapleural concentration with minimal systemic spread of the antineoplastic agent is required.…”

Section: Treatment Of Pleurodesis Failurementioning

confidence: 99%